What is Preimplantation Genetic Diagnosis (PGD) - Global Market?
Preimplantation Genetic Diagnosis (PGD) is a sophisticated technique used in the field of reproductive medicine to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy. This process involves the extraction of a few cells from an embryo to test for specific genetic conditions, ensuring that only healthy embryos are implanted into the uterus. PGD is particularly beneficial for couples at risk of passing on genetic disorders, as it allows them to select embryos free from these conditions, thereby increasing the chances of a healthy pregnancy. The global market for PGD is expanding as more people become aware of its potential to prevent genetic diseases and improve reproductive outcomes. This growth is driven by advancements in genetic testing technologies, increased demand for IVF procedures, and a growing awareness of genetic disorders. As a result, the PGD market is becoming an integral part of the broader assisted reproductive technology (ART) sector, offering hope to many families worldwide.
Chromosomal Abnormalities, Gender Selection, X-linked Diseases, Aneuploidy, Single Gene Disorders, Others in the Preimplantation Genetic Diagnosis (PGD) - Global Market:
Preimplantation Genetic Diagnosis (PGD) is a versatile tool used to screen for various genetic conditions, including chromosomal abnormalities, gender selection, X-linked diseases, aneuploidy, single gene disorders, and others. Chromosomal abnormalities refer to any change in the normal structure or number of chromosomes, often leading to genetic disorders or developmental issues. PGD can detect these abnormalities, such as Down syndrome, by analyzing the chromosomal makeup of embryos. Gender selection, another application of PGD, allows parents to choose the sex of their child, which can be important for avoiding sex-linked genetic diseases. X-linked diseases are genetic disorders caused by mutations in genes on the X chromosome. Since males have only one X chromosome, they are more likely to be affected by these disorders. PGD can identify embryos at risk of X-linked diseases, enabling parents to select unaffected embryos. Aneuploidy is a condition where embryos have an abnormal number of chromosomes, which can lead to miscarriages or genetic disorders. PGD helps in identifying aneuploid embryos, thus improving the chances of a successful pregnancy. Single gene disorders are caused by mutations in a single gene and can lead to serious health issues. PGD can screen for these disorders, such as cystic fibrosis or sickle cell anemia, allowing parents to select embryos without these mutations. The "others" category in PGD applications includes a range of genetic conditions that can be screened for, depending on the specific needs of the parents and the capabilities of the testing facility. The global market for PGD is expanding as more people become aware of its potential to prevent genetic diseases and improve reproductive outcomes. This growth is driven by advancements in genetic testing technologies, increased demand for IVF procedures, and a growing awareness of genetic disorders. As a result, the PGD market is becoming an integral part of the broader assisted reproductive technology (ART) sector, offering hope to many families worldwide.
Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes in the Preimplantation Genetic Diagnosis (PGD) - Global Market:
The usage of Preimplantation Genetic Diagnosis (PGD) in various sectors such as maternity centers, fertility clinics, hospitals, diagnostic labs, service providers, research laboratories, and academic institutes is becoming increasingly prevalent. Maternity centers and fertility clinics are at the forefront of PGD application, as they provide comprehensive reproductive services to couples seeking to conceive. These centers utilize PGD to screen embryos for genetic disorders, thereby increasing the chances of a successful and healthy pregnancy. Hospitals also play a crucial role in the PGD market, offering advanced reproductive technologies and genetic counseling services. They often collaborate with fertility clinics and diagnostic labs to provide a seamless experience for patients undergoing PGD. Diagnostic labs are essential in the PGD process, as they conduct the genetic testing required to identify potential genetic abnormalities in embryos. These labs employ cutting-edge technologies and highly skilled professionals to ensure accurate and reliable results. Service providers, including companies specializing in genetic testing and reproductive health, contribute to the PGD market by offering specialized services and products that support the PGD process. Research laboratories and academic institutes are instrumental in advancing PGD technologies and methodologies. They conduct studies to improve the accuracy and efficiency of PGD, as well as explore new applications and potential benefits. These institutions also play a vital role in educating healthcare professionals and the public about the advantages and limitations of PGD. As the global market for PGD continues to grow, these sectors will play an increasingly important role in shaping the future of reproductive medicine and genetic testing.
Preimplantation Genetic Diagnosis (PGD) - Global Market Outlook:
The global pharmaceutical market was valued at approximately 1,475 billion USD in 2022, with expectations of a steady growth rate of 5% annually over the next six years. This growth trajectory highlights the robust expansion and increasing demand within the pharmaceutical industry. In comparison, the chemical drug market has shown a significant increase, rising from 1,005 billion USD in 2018 to an estimated 1,094 billion USD in 2022. This upward trend in the chemical drug market underscores the ongoing advancements and innovations in drug development and production. The pharmaceutical sector's growth is driven by factors such as an aging global population, rising prevalence of chronic diseases, and continuous advancements in medical research and technology. Additionally, the increasing focus on personalized medicine and targeted therapies is contributing to the expansion of the pharmaceutical market. As the industry continues to evolve, companies are investing heavily in research and development to bring new and innovative treatments to market. This dynamic landscape presents numerous opportunities for growth and development within the pharmaceutical and chemical drug markets, as they strive to meet the ever-changing needs of patients and healthcare providers worldwide.
| Report Metric | Details |
| Report Name | Preimplantation Genetic Diagnosis (PGD) - Market |
| CAGR | 5% |
| Segment by Type: |
|
| Segment by Application |
|
| By Region |
|
| By Company | Illumina, Thermo Fisher, Agilent Technologies, PerkinElmer, Coopersurgical, Abbott Laboratories, Natera, Takara Bio, Oxford Gene Technology, Yikon Genomics, Progenesis, Beijing Genomics Institute, Invitae, Invicta Genetics, Combimatrix, Genea Limited, Bioarray, Quest Diagnostics |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
